Brilitas Pharmaceuticals EU OÜ — Financial statements & reports

Name: Datreal.com Company Registry
Creator: Datreal.com
License: https://opendatacommons.org/licenses/by/1.0/

Income statement

Income statement
Year	Revenue	Inventory changes	Long-term investment expenses	Other operating income (by nature)	Material expenses	Labour expenses	Depreciation	Cost of goods sold	Gross profit	Selling expenses	Administrative expenses	Other operating income (by function)	Other operating expenses	Profit from equity investments	Other long-term investment income	Interest income	Investment revaluation	Interest expenses	Extraordinary income	Extraordinary expenses	Profit before taxes	Income tax provisions	Profit after taxes	Other taxes	Extraordinary dividends	Net profit
2024	24 000 €	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14 854 €
2023	0 €	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1451 €

Year	Assets					Assets					Liabilities				Equity		Total liabilities & equity
Year	Cash	Securities	Receivables	Inventories	Total current assets	Investments	Intangible assets	Fixed assets	Total non-current assets	Total assets	Future housing repairs	Current liabilities	Non-current liabilities	Provisions	Capital	Total equity	Total liabilities & equity
2024	29 924 €	-	-	-	4415 €	-	-	-	-	-	-	-	-	-	34 339 €	-	-
2023	-	-	-	-	114 €	-	-	-	-	-	-	1565 €	-	-	-1451 €	-	-

Year	Operating cash flow	Investing cash flow	Financing cash flow	Net cash change
2024	Not available
2023	Not available

Year	Total taxes	Change	Social tax	Employees
2026	0 €	100.0%	0 €	-
2025	2095 €	189.0%	121 €	-
2024	725 €	-	729 €	1